Brought to you by 
Amylin and Glaxo to jointly research diabetes and obesity
29 Oct 2019
Executive Summary
Amylin and Glaxo Inc. have agreed to collaborate in the research of diabetes and obesity therapies involving Amylin's research on the pancreatic hormone amylin. Amylin retains diagnostic rights to the technology.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Joint Venture
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Amylin and Glaxo to jointly research diabetes and obesity
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice